These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 14561005)

  • 1. Fatal cholestatic liver failure associated with gemcitabine therapy.
    Robinson K; Lambiase L; Li J; Monteiro C; Schiff M
    Dig Dis Sci; 2003 Sep; 48(9):1804-8. PubMed ID: 14561005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fatal case of cholestatic liver failure probably related to gemcitabine.
    Coeman DC; Verbeken EK; Nackaerts KL; Demedts MG; Vansteenkiste JF
    Ann Oncol; 2000 Nov; 11(11):1503. PubMed ID: 11142494
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe acute lung injury induced by gemcitabine.
    Linskens RK; Golding RP; van Groeningen CJ; Giaccone G
    Neth J Med; 2000 Jun; 56(6):232-5. PubMed ID: 10821980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute liver failure secondary to gemcitabine.
    Stellman A; Loke MM; Mann S
    BMJ Case Rep; 2010 Apr; 2010():. PubMed ID: 22736319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.
    Tse AN; Wu N; Patel D; Haviland D; Kemeny N
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):935-44. PubMed ID: 19221752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
    Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gemcitabine-induced tumor lysis syndrome caused by recurrent breast cancer in a patient without hemodialysis].
    Kawaguchi Ushio A; Hattori M; Kohno N; Kaise H; Iwata H
    Gan To Kagaku Ryoho; 2013 Nov; 40(11):1529-32. PubMed ID: 24231708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
    Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
    Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy.
    Vander Els NJ; Miller V
    Chest; 1998 Dec; 114(6):1779-81. PubMed ID: 9872221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine.
    Ciotti R; Belotti G; Facchi E; Cantù A; D'Amico A; Gatti C
    Ann Oncol; 1999 Aug; 10(8):997. PubMed ID: 10509166
    [No Abstract]   [Full Text] [Related]  

  • 11. Fatal pulmonary veno-occlusive disease possibly related to gemcitabine.
    Vansteenkiste JF; Bomans P; Verbeken EK; Nackaerts KL; Demedts MG
    Lung Cancer; 2001 Jan; 31(1):83-5. PubMed ID: 11162870
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.
    Galvão FH; Pestana JO; Capelozzi VL
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):607-10. PubMed ID: 19904536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].
    Dahan L; Ressiot E; Cournede A; Ries P; Duluc M; Laquiere A; Laugier R; Braguer D; Seitz JF
    Gastroenterol Clin Biol; 2007 Dec; 31(12):1143-5. PubMed ID: 18176375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
    Schüll B; Scheithauer W; Kornek GV
    Onkologie; 2003 Dec; 26(6):578-80. PubMed ID: 14709934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A 42-year-old patient with the hemolytic-uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine].
    Eckel F; Lersch C; Erdmann J; Schmidt B; Schulte-Frohlinde E
    Z Gastroenterol; 2000 Jul; 38(7):593-6. PubMed ID: 10965557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Possinger K; Kaufmann M; Coleman R; Stuart NS; Helsing M; Ohnmacht U; Arning M
    Anticancer Drugs; 1999 Feb; 10(2):155-62. PubMed ID: 10211545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse alveolar damage in a patient treated with gemcitabine.
    Marruchella A; Fiorenzano G; Merizzi A; Rossi G; Chiodera PL
    Eur Respir J; 1998 Feb; 11(2):504-6. PubMed ID: 9551762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine-induced pseudocellulitis: a case report and review of the literature.
    Bami H; Goodman C; Boldt G; Vincent M
    Curr Oncol; 2019 Oct; 26(5):e703-e706. PubMed ID: 31708665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients.
    Locker GJ; Wenzel C; Schmidinger M; Gnant MF; Marosi C; Jakesz R; Zielinski CC; Steger GG
    Anticancer Drugs; 2001 Mar; 12(3):209-12. PubMed ID: 11290868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy.
    Saadati H; Peccerillo J; Kaley K; Schilsky ML; Saif MW
    JOP; 2009 Sep; 10(5):573-5. PubMed ID: 19734642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.